1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 6 1.2 List of Figures 6 2 Introduction 9 2.1 Therapy Area Introduction 9 2.2 Human Immunodeficiency Virus (HIV) 9 2.2.1 Overview 9 2.2.2 Symptoms 10 2.2.3 Co-morbidities and Complications 10 2.2.4 Epidemiology 11 2.3 Hepatitis C Virus 12 2.3.1 Overview 12 2.3.2 Symptoms 13 2.3.3 Co-morbidities and Complications 13 2.3.4 Epidemiology 14 2.4 Hepatitis B Virus 14 2.4.1 Overview 14 2.4.2 Symptoms 15 2.4.3 Co-morbidities and Complications 15 2.4.4 Epidemiology 16 2.5 Influenza 16 2.5.1 Overview 16 2.5.2 Symptoms 17 2.5.3 Co-morbidities and Complications 17 2.5.4 Epidemiology 17 2.6 Etiology and Pathogenesis of Viral Infections 18 2.7 Treatment for Viral Infections 19 2.7.1 Vaccines 19 2.7.2 Antiviral Agents 20 3 Marketed Products 22 3.1 Multiple Indications 22 3.1.1 Viread - Gilead 22 3.1.2 Epivir/Epivir-HBV - ViiV Healthcare 23 3.1.3 Pegasys - F. Hoffmann La Roche 25 3.2 Human Immunodeficiency Virus (HIV) 26 3.2.1 Truvada - Gilead 26 3.2.2 Atripla - Gilead 28 3.2.3 Stribild - Gilead 29 3.2.4 Tivicay - ViiV Healthcare 31 3.2.5 Triumeq - ViiV Healthcare 32 3.2.6 Genvoya - Gilead 33 3.3 Hepatitis C Virus (HCV) 35 3.3.1 Olysio - Janssen 35 3.3.2 Sovaldi and Harvoni - Gilead 36 3.3.3 Zepatier - Merck and Co. 38 3.4 Hepatitis B Virus 39 3.4.1 Baraclude - Bristol-Myers Squibb 39 3.5 Influenza Virus 40 3.5.1 Tamiflu - Roche 40 4 Pipeline 42 4.1 Overview 42 4.2 Pipeline Products by Stage of Development and Molecule Type 42 4.3 Pipeline Products by Molecular Target 47 4.4 Clinical Trials Landscape 50 4.4.1 Clinical Trial Failure Rates 51 4.4.2 Clinical Trial Duration 54 4.4.3 Clinical Trial Size 57 4.4.4 Cumulative Clinical Trial Size 61 4.4.5 Conclusion 63 4.5 Assessment of Key Pipeline Products 63 4.5.1 Sofosbuvir in Combination with Velpatasvir - Gilead 63 4.5.2 Tenofovir alafenamide fumarate - Gilead 65 4.5.3 Descovy - Gilead 66 4.5.4 Cobicistat, darunavir, emtricitabine and TAF - Johnson & Johnson 67 4.5.5 Beclabuvir hydrochloride - Bristol-Myers Squibb 68 4.5.6 V-212 - Merck 69 5 Multi-scenario Market Forecast to 2021 71 5.1 Revenues Analysis by Molecular Target 73 5.1.1 Reverse Transcriptase 73 5.1.2 Nonstructural Protein 5B Polymerase and Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A 74 5.1.3 HIV Integrase 75 5.1.4 Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase 76 5.1.5 NS3-4A Protease/Nonstructural Protein 5A 77 5.2 Revenue and Market Share Analysis by Company 78 5.2.1 Gilead Sciences - Monopolization of Market to Continue Throughout 2021 81 5.2.2 Merck - Uptake of Zepatier and Gardasil 9 to Encourage Strong Growth 82 5.2.3 GlaxoSmithKline - Tivicay and Triumeq to Propel Company Revenues 83 5.2.4 Johnson and Johnson - Market Share to Dwindle as Sales for Prezista and Olysio Decline 85 5.2.5 Bristol-Myers Squibb - Marginalization Due to Patent Expirations 86 6 Company Analysis and Positioning 87 6.1 Company Landscape 87 7 Strategic Consolidations 90 7.1 Licensing Deals 90 7.1.1 Deals by Region, Value, Year and Indication 90 7.1.2 Deals by Stage of Development and Value 92 7.1.3 Deals by Molecule Type, Molecular Target and Value 93 7.2 Co-development Deals 98 7.2.1 Deals by Region, Value, Year and Indication 98 7.2.2 Deals by Stage of Development and Value 100 7.2.3 Deals by Molecule Type, Molecular Target and Value 101 8 Appendix 104 8.1 References 104 8.2 Abbreviations 112 8.3 Table of All Pipeline Products 113 8.4 Methodology 177 8.4.1 Coverage 177 8.4.2 Secondary Research 177 8.4.3 Market Size and Revenue Forecasts 178 8.4.4 Pipeline Analysis 178 8.4.5 Competitive Landscape 179 8.5 Contact Us 179 8.6 Disclaimer 179

1.1 List of Tables Table 1: Common Routes of Viral Entry 18 Table 2: Viral Infections Therapeutics Market, Global, Licensing Deals Valued Above $100m, 2006-2016 95 Table 3: Viral Infections Therapeutics Market, Global, Co-development Deals Valued Above $100m, 2006-2016 103 Table 4: Table of All Pipeline Products 113 1.2 List of Figures Figure 1: Viral Infections Therapeutics Market, Major Markets, HIV Prevalence (‘000), 2014-2021 12 Figure 2: Viral Infections Therapeutics Market, Major Markets, HCV Prevalence (‘000), 2014-2021 14 Figure 3: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Viread ($m), 2006-2021 23 Figure 4: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Epivir/Epivir-HBV ($m), 2006-2021 24 Figure 5: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Pegasys ($m), 2006-2021 26 Figure 6: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Truvada ($bn), 2006-2021 28 Figure 7: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Atripla ($bn), 2006-2021 29 Figure 8: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Stribild ($bn), 2012-2021 30 Figure 9: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tivicay ($bn), 2013-2021 31 Figure 10: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Triumeq ($bn), 2015-2021 33 Figure 11: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Genvoya ($bn), 2016-2021 34 Figure 12: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Olysio ($m), 2013-2021 36 Figure 13: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Sovaldi and Harvoni ($bn), 2013-2021 37 Figure 14: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Zepatier ($bn), 2016-2021 38 Figure 15: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Baraclude ($m), 2006-2021 40 Figure 16: Viral Infections Therapeutics Market, Global, Historic and Forecast Annual Revenues for Tamiflu ($m), 2006-2021 41 Figure 17: Overall Pharmaceutical Industry Pipeline by Therapy Area, Global, 2016 42 Figure 18: Viral Infections Therapeutics Market, Global, Pipeline for Viral Infections by Stage of Development and Molecule Type, 2016 43 Figure 19: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Stage of Development, 2016 45 Figure 20: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecule Type, 2016 46 Figure 21: Viral Infections Therapeutics Market, Global, Pipeline by Molecular Target and Stage of Development, 2016 48 Figure 22: Viral Infections Therapeutics Market, Global, Breakdown of Viral Surface Protein, Immune Mediator and Polymerase Molecular Targets, 2016 49 Figure 23: Viral Infections Therapeutics Market, Global, Pipeline for Key Indications by Molecular Target, 2016 50 Figure 24: Viral Infections Therapeutics Market, Global, Clinical Trial Failure Rates by Stage of Development and Overall Clinical Trial Attrition Rate (%), 2006-2016 51 Figure 25: Viral Infections Therapeutics Market, Global, Clinical Trial Failure and Attrition Rates by Indication and Stage of Development (%), 2006-2016 52 Figure 26: Viral infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecule Type (%), 2006-2016 53 Figure 27: Viral Infections Therapeutics Market, Global, Clinical Trial Attrition Rates by Stage of Development and Molecular Target (%), 2006-2016 54 Figure 28: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Indication and Stage of Development (Months), 2006-2016 55 Figure 29: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecule Type and Stage of Development (Months), 2006-2016 56 Figure 30: Viral Infections Therapeutics Market, Global, Clinical Trial Duration by Molecular Target and Stage of Development (Months), 2006-2016 57 Figure 31: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Indication and Stage of Development (Participants), 2006-2016 58 Figure 32: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016 59 Figure 33: Viral Infections Therapeutics Market, Global, Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016 60 Figure 34: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Indication and Stage of Development (participants), 2006-2016 61 Figure 35: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecule Type and Stage of Development (participants), 2006-2016 62 Figure 36: Viral Infections Therapeutics Market, Global, Cumulative Clinical Trial Recruitment Size by Molecular Target and Stage of Development (participants), 2006-2016 63 Figure 37: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Sofosbuvir in Combination with Velpatasvir ($bn), 2016-2021 65 Figure 38: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for TAF ($bn), 2016-2021 66 Figure 39: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Descovy ($bn), 2016-2021 67 Figure 40: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Cobicistat in combination with darunavir, emtricitabine and TAF ($bn), 2016-2021 68 Figure 41: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for Beclabuvir Hydrochloride ($bn), 2016-2021 69 Figure 42: Viral Infections Therapeutics Market, Global, Forecast Annual Revenues for V-212 ($m), 2017-2021 70 Figure 43: Viral Infections Therapeutics Market, Global, Market Size ($bn), 2014-2021 71 Figure 44: Viral Infections Therapeutics Market, Global, Forecast Revenues for Strongest Commercial Products, 2014-2021 72 Figure 45: Viral Infections Therapeutics Market, Global, Premium and Generic Market Share ($bn), 2014-2021 73 Figure 46: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Reverse Transcriptase ($bn), 2014-2021 74 Figure 47: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Nonstructural Protein 5B Polymerase/Nonstructural Protein 5A, ($bn), 2014-2021 75 Figure 48: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting HIV Integrase, ($bn), 2014-2021 76 Figure 49: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting Cytochrome P450 3A4/Cytochrome P450 3A5/HIV-1 Integrase/Reverse Transcriptase, ($bn), 2014-2021 77 Figure 50: Viral Infections Therapeutics Market, Global, Sales Revenues for Products Targeting NS3-4A Protease/Nonstructural Protein 5A, ($bn), 2014-2021 78 Figure 51: Viral Infections Therapeutics Market, Global, Revenues by Company, 2014-2021 78 Figure 52: Viral Infections Therapeutics Market, Global, Companies by Compound Annual Growth Rate (CAGR), 2014-2021 79 Figure 53: Viral Infections Therapeutics Market, Global, Companies by Market Share, 2014-2021 79 Figure 54: Viral Infections Therapeutics Market, Revenues by Route of Acquisition, 2014-2021 80 Figure 55: Viral Infections Therapeutics Market, Gilead Sciences Annual Revenues ($bn), 2014-2021 81 Figure 56: Viral Infections Therapeutics Market, Global, Gilead Sciences Annual Revenues by Product ($m), 2014-2021 82 Figure 57: Viral Infections Therapeutics Market, Merck Annual Revenues ($bn), 2014-2021 83 Figure 58: Viral Infections Therapeutics Market, Global, Merck Annual Revenues by Product ($m), 2014-2021 83 Figure 59: Viral Infections Therapeutics Market, GlaxoSmithKline Annual Revenues ($bn), 2014-2021 84 Figure 60: Viral Infections Therapeutics Market, Global, GlaxoSmithKline Annual Revenues by Product ($m), 2014-2021 84 Figure 61: Viral Infections Therapeutics Market, Johnson and Johnson Annual Revenues ($bn), 2014-2021 85 Figure 62: Viral Infections Therapeutics Market, Global, Johnson and Johnson Annual Revenues by Product ($m), 2014-2021 85 Figure 63: Viral Infections Therapeutics Market, Bristol-Myers Squibb Annual Revenues ($bn), 2014-2021 86 Figure 64: Viral Infections Therapeutics Market, Global, Bristol-Myers Squibb Annual Revenues by Product ($m), 2014-2021 86 Figure 65: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016 87 Figure 66: Viral Infections Therapeutics Market, Global High-Activity and Late-Stage Pipeline Developers by Company Type, 2006-2016 88 Figure 67: Viral Infections Therapeutic Market, Global, Proportion of Total Company Revenue Attributed to Viral Infection Products, 2014-2021 89 Figure 68: Viral Infections Therapeutics Market, Global, Licensing Deals by Region, Deal Value and Year, 2006-2016 91 Figure 69: Viral Infections Therapeutics Market, Global, Licensing Deals by Indication and Deal Value, 2006-2016 92 Figure 70: Viral Infections Therapeutics Market, Global, Licensing Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016 93 Figure 71: Viral Infections Therapeutics Market, Global, Licensing Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016 94 Figure 72: Viral Infections Therapeutics Market, Global, Co-development Deals by Region, Deal Value and Year, 2006-2016 99 Figure 73: Viral Infections Therapeutics Market, Global, Co-development Deals by Indication and Deal Value, 2006-2016 100 Figure 74: Viral Infections Therapeutics Market, Global, Co-development Deals by Deal Value, Upfront Payment Value and Stage of Development, 2006-2016 101 Figure 75: Viral Infections Therapeutics Market, Global, Co-development Deals by Molecule Type, Molecular Target and Deal Value, 2006-2016 102